da terapia com fotobiomodulação no equilíbrio entre células T efetoras/ T reguladoras em modelo experimental de doença pulmonar obstrutiva crônica

• Ano de defesa: 2023
• Autor(a) principal: Alves, Cintia Estefano
• Orientador(a): Oliveira, Ana Paula Ligeiro de
• Banca de defesa: Oliveira, Ana Paula Ligeiro de , Franco, Adriana Lino dos Santos , Carvalho, Flávio Aimbire Soares de
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Nove de Julho
• Programa de Pós-Graduação: Programa de Pós-Graduação em Medicina – Biofotônica
• Departamento: Saúde
• País: Brasil
• Palavras-chave em Português: DPOC; laser; fotobiomodulação; inflamação pulmonar; citocinas
• Palavras-chave em Inglês: COPD; laser; photobiomodulation; lung inflammation; cytokines
• Área do conhecimento CNPq: CIENCIAS DA SAUDE
• Link de acesso: http://bibliotecatede.uninove.br/handle/tede/3765

Currently, COPD has a high impact on morbidity and mortality worldwide. The smoking habit, smoking history, airflow rate, obstruction and pulmonary emphysema are all related to the increase in the number of these CD4+, CD8+ cells expressing NF-κB, STAT4, IFN-𝛄 and perforin. On the other hand, a deficiency in T cells regulating CD4+CD25+Foxp3+ (Tregs) may impair the immune system and thus lead to immune disease. Thus, immunotherapeutic strategies, such as photobiomodulation (PBM) therapy, aim to regulate the levels of cytokines, chemokines and transcription factors. In this sense, the objective was to evaluate STAT4 and Foxp3 Treg cells as well as the production of IFN-g and IL-10 in the lung after PBM therapy in the COPD model. Thus, animals C57BL/6 with COPD submitted to diode laser therapy (660nm, 30mW, 180s) for 15 days. The protocol used for the induction of COPD consisted in the application orotracheal of extract of cigarette smoke (3x per week/7 weeks). Bronchoalveolar lavage (BAL) and lungs were collected for analysis. Data were submitted to the One-way ANOVA test followed by the NewmanKeuls test. Significance levels adjusted to 5% (p<0.05). PBM reduced the number of inflammatory cells, the levels of IL1-β, TNF-α, IL-6, IFN-γ, MCP-1, GM-CSF, KC/CXCL1, LTB4 and increased IL-10. We also observed decrease of collagen, mucus, bronchoconstriction index, alveolar enlargement, CD4+, CD8+, CD4+STAT4+ and CD4+IFN-γ+. In addition, in the treated group, we found an increase in T cells CD4+CD25+Foxp3+ and CD4+IL-10+. Thus, PBM treatment can be used as an immunotherapeutic strategy for COPD, through the possible mechanism of expansion of T reg cells population.